Physician profile
Jonathan Q Purnell
NPI 1144236639
$211,890.30
in general payments reported to CMS, 2019-2025
13 companies · $49K in 2025
The $49K reported for 2025 was more than what 96% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35K · 2020: $5,100 · 2021: $9,302 · 2022: $38K · 2023: $48K · 2024: $27K · 2025: $49K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $88K · Travel and Lodging: $32K · Food and Beverage: $4,041 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $88,376.75 |
| Travel and Lodging | $31,812.06 |
| Food and Beverage | $4,040.66 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk As | $108,423.74 | 2019-2025 | |
| Novo Nordisk INC | $66,618.27 | 2019-2025 | Ozempic, Wegovy |
| Boehringer Ingelheim International Gmbh | $15,541.58 | 2022 | |
| Regeneron Pharmaceuticals, INC. | $11,108.84 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $8,994.22 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $618.81 | 2023 | |
| Eli Lilly and Company | $260.23 | 2023-2024 | |
| Lilly USA, LLC | $208.70 | 2024-2025 | Zepbound |
| Amgen INC. | $90.00 | 2021 | |
| Madrigal Pharmaceuticals | $25.91 | 2025 | Rezdiffra |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Purnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.